iiinova — where your digital self keeps evolving

William Oh, MD @williamohmd.bsky.social · 22/01/2025

Incidence rates for male cancers published by @pubs.acs.org. #ProstateCancer incidence spiking again? Why? Is it just an aging population? More PSA testing? Guidelines changing? @yalecancer.bsky.social

292

William Oh, MD @williamohmd.bsky.social · 10/01/2025

I am reposting to highlight 2 other terms we hope we can gain consensus around: ARPI (rather than ARSI, NHT etc) and Combination therapy for mHSPC (instead of doublet/triplet or treatment intensification). Please read the rationale in this short editorial. @yalecancer.bsky.social

170

Reposted by William Oh, MD

Jack Iwashyna @iwashyna.bsky.social · 02/01/2025

Fascinating! “Most study participants (44-61%) could not extract basic information—including whether they have cancer—from standard prostate cancer pathology reports but [in contrast] 93% were able to understand this diagnostic information from” patient-centered pathology reports

2184

William Oh, MD @williamohmd.bsky.social · 20/12/2024

Precision med includes imaging to individualize care. Of 593 biopsy-naive men, 48% had (-) prostate MRIs and were followed. After 3 yrs of monitoring, clinically significant prostate cancer was detected in 4% of men with negative MRIs. Avoiding biopsies can be considered if MRI is (-)

jamanetwork.com

Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer

This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year active monitoring.

161

William Oh, MD @williamohmd.bsky.social · 10/12/2024

Thanks to @yaledailynews.bsky.social for covering my journey back to Yale and @yalecancer.bsky.social to bring #precisionmedicine to the next era. yaledailynews.com/blog/2024/12...

yaledailynews.com

290

William Oh, MD @williamohmd.bsky.social · 03/12/2024

How often is AS/WW used in int risk prostate cancer? Leapman et al @yalecancer.bsky.social report in JAMA that AS/WW use increased from 5 - 12.3% from 2010-20, most in GG1 dz. Treat high-risk disease early, but offer AS/WW for low + some int risk cancers. jamanetwork.com/journals/jam...

jamanetwork.com

Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer

This cross-sectional study evaluates trends and factors associated with selecting active surveillance or watchful waiting among individuals with intermediate-risk prostate cancer.

0113

William Oh, MD @williamohmd.bsky.social · 27/11/2024

#ProstateCancer screening is complicated. Unfortunately, recommendations re: screening are confusing--to the population, to those at high risk, and to physicians, as well. Can we better coordinate our guidelines among major cancer organizations? jamanetwork.com/journals/jam...

jamanetwork.com

How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening?

This Viewpoint explores how guideline groups can come together to agree on a framework that produces clear and unified recommendations.

2145

Reposted by William Oh, MD

Eric Feigl-Ding @drericding.bsky.social · 23/11/2024

Vaccines against COVID-19 saved over 20 million lives in the first year alone, according to a study in Lancet Infectious Diseases. Anti vaxxers conveniently ignore such stats.

442081653

Reposted by William Oh, MD

Matt Cooperberg @dr-coops.bsky.social · 23/11/2024

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

14019

Reposted by William Oh, MD

Carl Quintanilla @carlquintanilla.bsky.social · 22/11/2024

“.. After an hour or so of scrolling through Bluesky the other night, I felt something I haven’t felt on social media in a long time: free. “.. Free from Elon Musk, and his tedious quest to turn X into a right-wing echo chamber ..” @kevinroose.com www.nytimes.com/2024/11/22/t...

nytimes.com

Bluesky Is Turning Into a Strong X Alternative

Bluesky has a hint of the old Twitter magic, but the feeling of freedom it offers might be even better.

1127139

William Oh, MD @williamohmd.bsky.social · 21/11/2024

The Chemotherapy+ Foundation was founded 55 years ago to seek out new treatments for cancer patients. I am honored to Chair the Medical Advisory Council for TCF. We had our #InnovationGala at Gustavino's and awarded Roy Herbst, MD the Ezra Greenspan award, presented by Rob Winn and Katie Politi.

240

William Oh, MD @williamohmd.bsky.social · 18/11/2024

Words matter in medicine: for accuracy among clinicians + researchers, and for patients, to understand their disease. We propose avoiding “castration” by unifying around HSPC and coin a new phrase ARPC for “androgen deprivation resistant prostate cancer” www.sciencedirect.com/science/arti...

sciencedirect.com

What’s in a Name? Why Words Matter in Advanced Prostate Cancer

2145

William Oh, MD @williamohmd.bsky.social · 17/11/2024

I think this suggests that cancer screening will continue to rely on understanding the heterogeneity of cancer and of people. At least for now.

021

William Oh, MD @williamohmd.bsky.social · 17/11/2024

I am excited to join this rapidly growing #medsky community! It’s time to grow a new forum for #science-driven information and communication. #prostatecancer #precisionmedicine #medicaloncology

1122